13.04
-0.05 (-0.38%)
| Penutupan Terdahulu | 13.09 |
| Buka | 13.00 |
| Jumlah Dagangan | 466,901 |
| Purata Dagangan (3B) | 591,655 |
| Modal Pasaran | 648,291,392 |
| Harga / Buku (P/B) | 4.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Jul 2025 - 14 Jul 2025 |
| EPS Cair (TTM) | -3.77 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.98% |
| Nisbah Semasa (MRQ) | 10.44 |
| Aliran Tunai Operasi (OCF TTM) | -127.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.82 M |
| Pulangan Atas Aset (ROA TTM) | -58.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | KalVista Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.38 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.47% |
| % Dimiliki oleh Institusi | 112.39% |
| Julat 52 Minggu | ||
| Median | 28.00 (114.72%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 08 Apr 2025 | 28.00 (114.72%) | Beli | 10.32 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |